A Digital Health Seminar Series event hosted by LEAP

Abstract: At AstraZeneca we harness data and technology to maximise time for the discovery and delivery of potential new medicines. Data science and artificial intelligence (AI) are embedded across our R&D to enable our scientists to push the boundaries of science to deliver life-changing medicines.

In this seminar, we will explore the cutting-edge advancements in digital health, focusing on the integration of AI and novel biomarkers to enhance diagnostic and therapeutic processes. The talk will cover a range of topics in the domain of machine perception.

The include vocal biomarkers, providing a non-invasive and accessible diagnostic tool for respiratory conditions. We will also discuss the latest developments in retinal imaging technologies and their applications in early detection of diseases such as diabetic retinopathy and age-related macular degeneration. Additionally, we’ll see advances in endoscopic techniques and AI-driven image analysis to improve the accuracy and efficiency of gastrointestinal diagnostics. We’ll also introduce EchoQC, a quality control system for echocardiography that leverages AI to ensure precise and reliable cardiac assessments.

Finally, we will present Evinova. AstraZeneca launched Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector.